A Phase 1, Randomized, Active-Comparator/Placebo-Controlled, Observer-Blinded Trial of the Safety, Tolerability, and Immunogenicity of 20 mg, 60 mg, and 200 mg of Meningococcal Group B rLP2086 Vaccine in Healthy Toddlers Aged 18 to 36 Months

Trial Profile

A Phase 1, Randomized, Active-Comparator/Placebo-Controlled, Observer-Blinded Trial of the Safety, Tolerability, and Immunogenicity of 20 mg, 60 mg, and 200 mg of Meningococcal Group B rLP2086 Vaccine in Healthy Toddlers Aged 18 to 36 Months

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2014

At a glance

  • Drugs PF 5212366 (Primary)
  • Indications Meningococcal group B infections
  • Focus Adverse reactions
  • Sponsors Wyeth
  • Most Recent Events

    • 11 May 2008 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 03 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top